At a Glance
- Company: AdvanCell
- Location: Australia and the U.S.
- Deal value: $315 million Series D
- Focus area: Prostate cancer radiopharmaceuticals
- Next steps: Advance the lead programme and expand U.S. manufacturing capacity
What happened?
AdvanCell has secured a $315 million Series D financing round to support development of its lead-based prostate cancer radiopharmaceutical candidate. The company is also using the money to strengthen U.S. manufacturing for a potential competitor to Novartis’ Pluvicto.
Why does it matter?
The raise shows investors remain willing to back radiopharmaceutical platforms, especially when the programme combines clinical ambition with manufacturing scale-up. It also reflects the importance of supply chain readiness in a field where patient access can depend on reliable production and distribution.
Who’s behind it?
AdvanCell is the company leading the programme, with a focus on radioactive payloads and prostate cancer. The financing supports both its clinical development work and the buildout of manufacturing infrastructure in the U.S.
How was it achieved?
The Series D is designed to fund ongoing development of a lead candidate while also creating the operational capacity needed for later commercialisation. That combination of clinical and manufacturing investment is especially important in radiopharma, where scale and reliability are as critical as efficacy.
What’s next?
AdvanCell will use the capital to push the candidate forward and expand its U.S. production capabilities. The company’s progress will likely be measured by both clinical data and how quickly it can establish a dependable supply base.